Every 8-K that ADC Therapeutics SA (ADCT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ADCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADCT filings page.
ADC Therapeutics reported second-quarter 2026 net product revenue of $18.6 million, roughly flat year over year, and total revenue of $19.2 million. Aggressive cost control cut total operating expenses to $44.7 million, down 29% from 2025, reducing the quarterly net loss to $16.6 million from $56.6 million. Adjusted operating expenses fell 22% to $37.2 million, and adjusted net loss narrowed to $16.3 million.
Cash and cash equivalents were $219.1 million at June 30, 2026, with the company stating an expected cash runway at least into 2028. A June 2026 reorganization, including a 17% workforce reduction, is expected to generate about $10 million in annualized savings.
On the clinical side, the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab met its primary PFS endpoint, but the FDA expressed substantial concerns about benefit–risk given an imbalance in Grade 5 events and marginal treatment benefit, leaving the full-approval path under evaluation. The LOTIS-7 Phase 1b trial of ZYNLONTA plus glofitamab completed enrollment and shows high complete response rates in relapsed/refractory DLBCL, with plans to seek Breakthrough Therapy designation and explore a Phase 3 program. Investigator-initiated trials in marginal zone and follicular lymphomas report high complete response rates and durable disease control, supporting potential compendia and regulatory strategies from 2027 onward.
ADC Therapeutics approved one-time retention awards for key executives to encourage them to stay with the company. On June 30, 2026, the board, advised by its independent compensation consultant, granted cash bonuses payable on or about July 15, 2026 and restricted stock units (RSUs) that vest after one year or upon certain terminations.
CEO Ameet Mallik will receive a cash incentive of $1,795,500 and 675,000 RSUs, CFO Jose Carmona will receive $541,842 and 203,700 RSUs, and Chief Medical Officer Mohamed Zaki will receive $568,974 and 213,900 RSUs. Executives must generally remain employed through June 30, 2027 to keep the cash awards and for RSUs to vest, except if they are terminated without cause or resign for good reason.
ADC Therapeutics is implementing a strategic reorganization centered on its ZYNLONTA franchise, including a global workforce reduction of approximately 17 percent. This move is tied to the expected completion of the LOTIS-5 and LOTIS-7 trials and to operational efficiencies.
The company expects the reorganization to generate annualized estimated cost savings of about $10 million, while incurring one-time pre-tax charges of roughly $3 million for severance, benefits and related termination costs, mostly in the second quarter of 2026. Management states it has an expected cash runway at least into 2028 and is preparing for an August 2026 pre-sBLA meeting with the FDA for LOTIS-5, with an sBLA submission planned for the fourth quarter of 2026 and full LOTIS-7 data anticipated by the end of 2026.
ADC Therapeutics reported topline Phase 3 LOTIS-5 results for ZYNLONTA plus rituximab in relapsed or refractory diffuse large B‑cell lymphoma. The study met its primary endpoint: progression‑free survival improved to a median 6.1 months versus 4.7 months with R‑GemOx (hazard ratio 0.73; p=0.008).
Overall response rate was higher at 58.1% versus 45.2%, with complete responses of 39.5% versus 26.7%. Median duration of response was 9.2 versus 7.7 months and complete responses lasted 16.8 versus 12.3 months, with 48.5% versus 16.7% of complete responders still in remission at 24 months.
Overall survival showed no detrimental effect (hazard ratio 0.96). Safety was mixed: overall treatment‑emergent adverse event rates were similar, but serious events, withdrawals, and Grade 5 events were higher with ZYNLONTA plus rituximab (Grade 5 in 13.2% versus 4.6%, mostly in patients aged 75 or older). The company plans a pre‑sBLA FDA meeting in August and a supplemental BLA submission in the fourth quarter of 2026.
ADC Therapeutics reported that shareholders approved all proposals at the 2026 annual general meeting on June 1, 2026. Investors endorsed the 2025 financial statements, discharged the board and executive committee from liability, and reelected all directors, compensation committee members, the Independent Proxy and PricewaterhouseCoopers as auditor.
Shareholders approved, on a binding Swiss-law basis, maximum board compensation of $2,500,000, fixed executive committee pay of $2,600,000 for 2027, and variable executive compensation of up to $5,500,000 for 2026. They also approved an amendment increasing shares authorized under the 2019 Equity Incentive Plan.
Key capital changes included raising the Company’s capital range to between CHF 10,378,109.12 and CHF 15,567,163.68, increasing conditional share capital for employee participation to 16,836,253 common shares, and for financing and acquisitions to 48,026,929 common shares, alongside introducing a new conditional share capital article based on the capital range.
ADC Therapeutics reported first quarter 2026 results, highlighting growing product sales but continuing losses. Net product revenue from ZYNLONTA reached $20.0 million, up from $17.4 million a year earlier, while total revenue was $20.9 million versus $23.0 million due to lower license revenue and royalties.
The company recorded a net loss of $33.0 million, improving from a $38.6 million loss in first quarter 2025. Adjusted net loss narrowed to $19.7 million, or $0.13 per share, from $24.0 million, or $0.22 per share, mainly driven by lower research and development spending.
Cash and cash equivalents were $231.0 million as of March 31, 2026, down from $261.3 million at year end 2025, and the company expects its cash runway to extend at least into 2028. Management also reiterated key clinical milestones, including LOTIS-5 Phase 3 topline data expected in the second quarter of 2026 and full LOTIS-5 and LOTIS-7 data anticipated by year end.
ADC Therapeutics reported higher 2025 sales of ZYNLONTA and narrower losses while outlining key trial milestones. Net product revenue reached $22.3 million in Q4 and $73.6 million for 2025, up from $16.4 million and $69.3 million in 2024. Q4 net loss shrank to $6.4 million versus $30.7 million a year earlier; full-year net loss improved to $142.6 million from $157.8 million.
Cash and cash equivalents were $261.3 million at December 31, 2025, with management expecting runway at least into 2028 after two 2025 PIPE financings that raised $150.8 million net. An amended HealthCare Royalty agreement cuts the change-of-control payment from $750 million to $150 million through 2027 and $200 million thereafter, in exchange for warrants for about 9.8 million shares at $3.81. The company expects LOTIS-5 Phase 3 topline data in Q2 2026 and full LOTIS-5 and LOTIS-7 data by year-end 2026, supporting potential regulatory and compendia steps from 2027 onward.
ADC Therapeutics amended its royalty financing with entities managed by HealthCare Royalty Management and issued new equity-linked securities. HCR has funded the Company with $300 million to date. Under the amended agreement, a change of control now triggers a payment to HCR of $150 million if it occurs on or before December 31, 2027, or $200 million if it occurs on or after January 1, 2028. Royalty payments continue after a change of control until reaching the Royalty Cap, unless bought out for $525 million on or before December 31, 2029 or $750 million on or after January 1, 2030, in each case reduced by prior royalties and the change of control payment.
In connection with this amendment, the Company issued HCR warrants to purchase 9,834,776 common shares at an exercise price of $3.8130 per share, exercisable until December 31, 2030. The warrants allow cash or cashless exercise, contain change-of-control mechanics that accelerate or transfer the warrants, restrict transferability until December 31, 2027, and include registration rights requiring the Company to file a resale registration statement for the underlying shares. The warrants were issued as an unregistered private offering under Section 4(a)(2) of the Securities Act.
ADC Therapeutics SA released an updated corporate presentation and furnished it as an exhibit to a current report. The presentation is attached as Exhibit 99.1 and is meant to provide investors and other stakeholders with more detail about the company and its activities. The company notes that this material is being furnished under Regulation FD, which is designed to ensure fair disclosure of information. The presentation and related information are not treated as formally filed financial statements and are not automatically incorporated into other securities law filings unless specifically referenced.
ADC Therapeutics SA reported that it has released preliminary estimates for its revenue for the quarter and year ended December 31, 2025, along with preliminary cash and cash equivalents as of that date. These figures were disclosed in a press release dated January 8, 2026, which is attached as an exhibit.
The company emphasized that these revenue and cash numbers are preliminary, unaudited and based on management’s complex judgments and estimates. Actual results for the quarter and full year 2025 are not yet finalized or reviewed by independent auditors and may differ materially from these early estimates. The information is being furnished for disclosure purposes and is not deemed filed under the securities laws unless specifically incorporated by reference.
ADC Therapeutics SA reported new clinical data from its ongoing LOTIS-7 Phase 1b open-label trial. This study evaluates the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma, a difficult-to-treat blood cancer. As of the November 17, 2025 cutoff date, 49 patients were considered efficacy evaluable, each with at least six months of follow-up from the start of treatment. These updated data help further characterize how this drug combination performs in heavily pretreated lymphoma patients.
ADC Therapeutics SA filed an 8‑K and furnished a press release announcing financial results for the quarter ended September 30, 2025.
The release is included as Exhibit 99.1 and, as stated under Item 2.02, the information is furnished and not deemed filed under the Exchange Act.
ADC Therapeutics SA entered into securities purchase agreements for a $60.0 million private placement of equity to institutional investors. The Company will sell 11,250,000 common shares at $4.00 per share and pre-funded warrants to purchase 3,846,153 common shares at $3.90 per warrant. Closing is expected on October 27, 2025, subject to customary conditions.
The Company agreed to file a registration statement within 30 business days to register the resale of the common shares and the common shares issuable upon exercise of the pre-funded warrants. The pre-funded warrants are exercisable until the tenth anniversary at an exercise price of CHF 0.08 per share, include a 9.99% beneficial ownership cap (which holders may increase to 19.99% after 61 days’ notice), and permit cashless exercise under specified conditions.
ADC Therapeutics SA furnished a current report to let investors know it has made an updated corporate presentation available. The presentation, dated September 30, 2025, is attached as Exhibit 99.1. The company notes that this material is being provided under Regulation FD and is not considered filed for liability purposes under the Exchange Act.
ADC Therapeutics SA reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The company filed a Current Report on Form 8-K to attach that press release as Exhibit 99.1, and the filing also includes a Cover Page Interactive Data File as Exhibit 104.
The filing states that the information in Item 2.02 and Exhibit 99.1 is incorporated by reference but shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. The report is signed on behalf of the company by Jose Carmona, Chief Financial Officer. The 8-K itself does not include the detailed financial tables or results within the body of the filing.